Loading...
Please wait, while we are loading the content...
Similar Documents
Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration.
| Content Provider | Europe PMC |
|---|---|
| Author | Kim, Min Seok Ryoo, Na-Kyung Park, Kyu Hyung |
| Abstract | This study aims to report the 12 months results of efficacy and safety of laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections for drusenoid pigment epithelial detachment (dPED). In this prospective study, patients with treatment naïve bilateral intermediate age-related macular degeneration, featuring dPED, with visual acuity ≤ 83 letters were enrolled. The study group received PASCAL laser (532 nm) along the periphery of the dPED, and the fellow eye served as a control group. To prevent complications of choroidal neovascularization, intravitreal anti-VEGF injections to laser treated eye were performed on a 3-month interval up to 1 year. Primary outcomes-drusen area, PED height-and secondary outcomes-best-corrected visual acuity (BCVA), contrast sensitivity, degree of metamorphopsia, NEI-VFQ 25, and fundus autofluorescence-were analyzed. Among 21 patients, a total of 20 patients satisfied the 12 months follow-up. Drusen area and PED height decreased significantly in the laser group, while no significant change appeared in the control group (74.1% vs. - 3.5%, P < 0.001; 76.6% vs. 0.1%, P < 0.001). Mean BCVA improved 4.6 letters in the laser group (vs. 1.1 letters in the control group, P = 0.019). As for safety, one study eye developed retinal pigment epithelial tear, and one control eye developed retinal angiomatous proliferation. Low energy laser photocoagulation and anti-VEGF injection in eyes with dPED showed some improvement in visual acuity. dPED regressed without developing center involving GA in the study eye, but a longer term follow-up is necessary to reveal the efficacy and safety of these treatments. The 2-year results of this study will be followed to reveal long term efficacy and safety of the treatment for dPED. |
| Journal | Scientific Reports [Sci Rep] |
| Volume Number | 10 |
| DOI | 10.1038/s41598-020-71401-3 |
| PubMed Central reference number | PMC7462975 |
| Issue Number | 1 |
| PubMed reference number | 32873842 |
| e-ISSN | 20452322 |
| Language | English |
| Publisher | Nature Publishing Group |
| Publisher Date | 2020-09-01 |
| Publisher Place | London |
| Access Restriction | Open |
| Subject Keyword | Macular degeneration Retinal diseases |
| Content Type | Text |
| Resource Type | Article |
| Subject | Multidisciplinary |
